Global Chronic Heart Failure (CHF) Devices Market Insights, Forecast to 2028

Market Analysis and Insights: Global Chronic Heart Failure (CHF) Devices Market
Due to the COVID-19 pandemic, the global Chronic Heart Failure (CHF) Devices market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Implantable Left Ventricular Assist Device (LVAD) accounting for % of the Chronic Heart Failure (CHF) Devices global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Chronic Heart Failure (CHF) Devices market size is valued at US$ million in 2021, while the US and Europe Chronic Heart Failure (CHF) Devices are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Chronic Heart Failure (CHF) Devices landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Chronic Heart Failure (CHF) Devices include Medtronic, Abbott, Johnson & Johnson, Stanley Pharmaceuticals, New Haven Pharmaceuticals, Inc., Boston Scientific Corporation, HeartWare, Biovail Corporation and Abiomed, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Chronic Heart Failure (CHF) Devices Scope and Segment
Chronic Heart Failure (CHF) Devices market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Chronic Heart Failure (CHF) Devices market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Implantable Left Ventricular Assist Device (LVAD)
Biventricular Pacemaker
Implantable Cardioverter-defibrillators (ICDs)
Continuous Positive Air Pressure Device (CPAP)
Bi-level Positive Air Pressure Device (BiPAP)
Heart Pumps
Segment by Application
Hospital
Clinic
Household
Others
By Company
Medtronic
Abbott
Johnson & Johnson
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Boston Scientific Corporation
HeartWare
Biovail Corporation
Abiomed
Symplmed Pharmaceuticals
Berlin Heart GmbH
ReliantHeart, Inc.
Cardiokinetix
Biotronik
Jarvik Heart
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE